← CG Oncology (CGON)

CG Oncology SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 4Nov. 18, 2026, 4:30 p.m. ETView on SEC.gov
  • 4Nov. 18, 2026, 4:30 p.m. ETView on SEC.gov
  • 4Nov. 17, 2026, 4:30 p.m. ETView on SEC.gov
  • 8-KNov. 16, 2026, 8:15 a.m. ETView on SEC.gov

    Regulation FD disclosure · Other events · Financial statements and exhibits

    AI summary, unreviewedCG Oncology Reports Positive Phase 3 PIVOT-006 Topline Data: 68% Reduction in Recurrence Risk (HR 0.32) in Intermediate-Risk and HG Ta NMIBC; BCG-Unresponsive BLA Timing Pushed to March 2027

  • 10-QNov. 6, 2026, 8:45 a.m. ETView on SEC.gov
  • 8-KNov. 6, 2026, 8:30 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits

    AI summary, unreviewedCG Oncology Q3 2026 EPS of -$0.64 Beats -$0.81 Consensus; Revenue $1.6 Million Tops $0.5 Million Estimate

  • 4Oct. 19, 2026, 4:30 p.m. ETView on SEC.gov
  • 4Oct. 19, 2026, 4:30 p.m. ETView on SEC.gov
  • 4Sept. 17, 2026, 4:30 p.m. ETView on SEC.gov
  • 4Aug. 18, 2026, 4:30 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 14, 2026, 7:58 a.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 14, 2026, 4:01 p.m. ETView on SEC.gov
  • SCHEDULE 13G/AAug. 13, 2026, 4:05 p.m. ETView on SEC.gov
  • 10-QAug. 6, 2026, 8:45 a.m. ETView on SEC.gov
  • 8-KAug. 6, 2026, 8:30 a.m. ETView on SEC.gov

    Results of operations and financial condition · Other events · Financial statements and exhibits

  • 424B5Aug. 6, 2026, 8 a.m. ETView on SEC.gov
  • SCHEDULE 13G/AJuly 27, 2026, 4:25 p.m. ETView on SEC.gov